Palisade Bio’s (PALI) Buy Rating Reiterated at Brookline Capital Management

Brookline Capital Management reiterated their buy rating on shares of Palisade Bio (NASDAQ:PALI) in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 target price on the stock.

Palisade Bio Price Performance

Shares of PALI opened at $0.68 on Tuesday. Palisade Bio has a 1-year low of $0.60 and a 1-year high of $6.46. The stock has a market cap of $3.26 million, a PE ratio of -0.05 and a beta of 1.46. The firm has a fifty day moving average price of $0.75 and a 200 day moving average price of $1.41.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.37. As a group, equities analysts expect that Palisade Bio will post -12.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PALI. JPMorgan Chase & Co. acquired a new position in Palisade Bio in the third quarter valued at $29,000. Armistice Capital LLC increased its stake in Palisade Bio by 37.4% in the first quarter. Armistice Capital LLC now owns 144,764 shares of the company’s stock valued at $99,000 after purchasing an additional 39,397 shares during the period. Finally, Cetera Investment Advisers acquired a new position in Palisade Bio in the fourth quarter valued at $116,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.